MedTrace Logo

Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus

NCT01954147 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2014-02-20

No results posted yet for this study

Summary

Umbilical cord mesenchymal stem cells (SC) transplantation was a novel therapy for diabetes mellitus, with less side effects and more advantages. Clinical trials had verified that good metabolic control would be achieved when Liraglutide (GLP-1) was added to the conventional therapies. The investigators hypothesized that the combined therapy of umbilical cord mesenchymal stem cells transplantation and Liraglutide in type 2 diabetes mellitus will aid the differentiation of stem cells into insulin-producing cells, improve the survival of differentiated cells, protect the residual beta-cells and improve insulin secreting function, so as to achieve a favorable glucose homeostasis.

Conditions

Interventions

DRUG

GLP-1

GLP-1 therapy

BIOLOGICAL

SC

Stem cell infusion

OTHER

Standard Medical Treatment

Standard Medical Treatment

Sponsors & Collaborators

  • Diabetes Care Center of Nanjing Military Command

    lead OTHER

Principal Investigators

  • Xiangjin Xu, Professor · Diabetes Care Center of Nanjing Millitary Command

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
35 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2014-10-31
Completion
2015-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01954147 on ClinicalTrials.gov